INOLYSIS – LEADS FOR FIBROSIS

TARGETING FIBROBLASTS TO COMBAT CHRONIC INFLAMMATORY AND FIBROTIC DISEASES

WHO WE ARE

Our team combines multidisciplinary experience in biology, pathophysiology, medicinal chemistry and preclinical testing.

Meet Our Team

OUR SCIENCE

INOLYSIS leverages a unique drug discovery pipeline that integrates medicinal chemistry, molecular phenotyping, in vitro and ex vivo assays, as well as in vivo efficacy and safety studies, combined with deep understanding of fibroblast biology.

Explore Our Science

OUR COLLABORATORS

Our collaborators are key partners in our mission to drive innovation. We are honored to work with leading research institutions, biotech companies, and industry experts committed to advancing scientific discovery and therapeutic development.

See Our Collaborators

More than 50 million people worldwide are affected by chronic fibrotic diseases.

$75 billion per year is spent on managing healthcare expenses linked to fibrotic complications.

Over 20% of cancer patients face treatment challenges due to underlying fibrotic tissue changes.

Clients

OUR COLLABORATORS

Contact

TARGETING FIBROBLASTS TO COMBAT CHRONIC INFLAMMATORY AND FIBROTIC DISEASES

WHO WE ARE

OUR SCIENCE

OUR COLLABORATORS

OUR COLLABORATORS

CONTACT US